<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03523065</url>
  </required_header>
  <id_info>
    <org_study_id>CPD-GBAR</org_study_id>
    <nct_id>NCT03523065</nct_id>
  </id_info>
  <brief_title>Chinese PD-GBA Registry</brief_title>
  <official_title>The Chinese Parkinson's Disease With GBA Variants Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Chinese Parkinson's disease with GBA variants Registry (CPD-GBAR) is to
      develop a database of patients of Parkinson's disease with Glucocerebrosidase (GBA) gene
      variants in mainland China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) is the second most common disorder among neurodegenerative diseases.
      GBA gene variants such as L444P can influence the risk of developing PD and these variants
      have the greatest impact on PD susceptibility among all the PD related gene variants yet
      discovered. The investigators aim to establish a database of PD with GBA variants and
      characterize the clinical manifestation of these patients in mainland China.

      Method:

        1. Peripheral blood from patients has been tested to have GBA gene variants.

        2. Clinical manifestation will be measured by scales and neurological tests. Standard
           scales include: Unified Parkinson's Disease Rating Scale(UPDRS), Hoehn-Yahr stages,
           Non-Motor Symptoms Scale (NMSS), mini-mental state examination (MMSE), Parkinson disease
           sleep scales (PDSS), Rapid Eye Movement Sleep Behaviour Disorder Questionnaire(RBDQ-HK),
           Epworth Sleepiness Scale (ESS), Rome III functional constipation scale, the Scale for
           Outcomes in PD for Autonomic Symptoms (SCOPA-AUT), Parkinson Fatigue Scale (PFS),
           Cambridge-Hopkins Restless Legs Syndrome questionnaire (CHRLSq), Hyposmia rating
           scale(HRS), Hamilton depression scale, the 39-item Parkinson's Disease
           Questionnaire(PDQ-39), Freezing of gait scale(FOG), dyskinesia related scales,
           Wearing-off scale(WO).

        3. The investigators will also exam the blood biomarkers of PD such as uric acid and
           peripheral inflammatory markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Database of Parkinson's disease with GBA variants</measure>
    <time_frame>10 years</time_frame>
    <description>Establish the database of Parkinson's disease with GBA variants in mainland China.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical feature</measure>
    <time_frame>10 years</time_frame>
    <description>Characterize the clinical feature of PD patients with GBA variants</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Parkinson Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        PD patients with GBA gene variants
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with PD by the United Kingdom Parkinson's Disease Society Brain
             Bank clinical diagnostic criteria or other standard criteria; PD patients detected
             with GBA gene variants.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jifeng Guo, Ph.D.</last_name>
    <phone>+8613974936815</phone>
    <email>guojifeng2003@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beisha Tang, Ph.D.</last_name>
    <phone>+8613974856709</phone>
    <email>bstang7398@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jifeng Guo, Ph.D.</last_name>
      <phone>+8613974936815</phone>
      <email>guojifeng2003@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Qiying Sun, Ph.D.</last_name>
      <phone>+8615874907260</phone>
      <email>sunqiying2015@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang Y, Shu L, Sun Q, Zhou X, Pan H, Guo J, Tang B. Integrated Genetic Analysis of Racial Differences of Common GBA Variants in Parkinson's Disease: A Meta-Analysis. Front Mol Neurosci. 2018 Feb 15;11:43. doi: 10.3389/fnmol.2018.00043. eCollection 2018.</citation>
    <PMID>29527153</PMID>
  </reference>
  <results_reference>
    <citation>Sun QY, Guo JF, Wang L, Yu RH, Zuo X, Yao LY, Pan Q, Xia K, Tang BS. Glucocerebrosidase gene L444P mutation is a risk factor for Parkinson's disease in Chinese population. Mov Disord. 2010 Jun 15;25(8):1005-11. doi: 10.1002/mds.23009.</citation>
    <PMID>20131388</PMID>
  </results_reference>
  <results_reference>
    <citation>Guo JF, Li K, Yu RL, Sun QY, Wang L, Yao LY, Hu YC, Lv ZY, Luo LZ, Shen L, Jiang H, Yan XX, Pan Q, Xia K, Tang BS. Polygenic determinants of Parkinson's disease in a Chinese population. Neurobiol Aging. 2015 Apr;36(4):1765.e1-1765.e6. doi: 10.1016/j.neurobiolaging.2014.12.030. Epub 2015 Jan 6.</citation>
    <PMID>25623333</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang Y, Sun QY, Zhao YW, Shu L, Guo JF, Xu Q, Yan XX, Tang BS. Effect of GBA Mutations on Phenotype of Parkinson's Disease: A Study on Chinese Population and a Meta-Analysis. Parkinsons Dis. 2015;2015:916971. doi: 10.1155/2015/916971. Epub 2015 Sep 2.</citation>
    <PMID>26421210</PMID>
  </results_reference>
  <results_reference>
    <citation>Fan K, Tang BS, Wang YQ, Kang JF, Li K, Liu ZH, Sun QY, Xu Q, Yan XX, Guo JF. The GBA, DYRK1A and MS4A6A polymorphisms influence the age at onset of Chinese Parkinson patients. Neurosci Lett. 2016 May 16;621:133-136. doi: 10.1016/j.neulet.2016.04.014. Epub 2016 Apr 13.</citation>
    <PMID>27085534</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

